Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis

Windisch, Roman; Kozousek, V

doi:10.3129/i08-069

Cited by 6 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A potential benefit of short-term intravitreal VEGF inhibition on foveal detachment in MacTel type 2 has been reported (Lira et al, 2010; Maia Junior et al, 2007; Windisch and Kozousek, 2008). The foveal anatomy regained its normal configuration with improved visual acuity in several retrospectively analyzed cases.…”

Section: Treatmentmentioning

confidence: 99%

Macular telangiectasia type 2

Issa

Gillies

Chew

et al. 2013

Progress in Retinal and Eye Research

328

244

View full text Add to dashboard Cite

Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules, retinal pigment plaques, foveal atrophy, and neovascular complexes. Fluorescein angiography shows telangiectatic capillaries predominantly temporal to the foveola in the early phase and a diffuse hyperfluorescence in the late phase. High-resolution optical coherence tomography (OCT) may reveal disruption of the photoreceptor inner segment–outer segment border, hyporeflective cavities at the level of the inner or outer retina, and atrophy of the retina in later stages. Macular telangiectasia type 2 shows a unique depletion of the macular pigment in the central retina and recent therapeutic trials showed that such depleted areas cannot re-accumulate lutein and zeaxanthin after oral supplementation. There have been various therapeutic approaches with limited or no efficacy. Recent clinical trials with compounds that block vascular endothelial growth factor (VEGF) have established the role of VEGF in the pathophysiology of the disease, but have not shown significant efficacy, at least for the nonneovascular disease stages. Recent progress in structure–function correlation may help to develop surrogate outcome measures for future clinical trials. In this review article, we summarize the current knowledge on macular telangiectasia type 2, including the epidemiology, the genetics, the clinical findings, the staging and the differential diagnosis of the disease. Findings using retinal imaging are discussed, including fluorescein angiography, OCT, adaptive optics imaging, confocal scanning laser ophthalmoscopy, and fundus autofluorescence, as are the findings using visual function testing including visual acuity and fundus-controlled microperimetry. We provide an overview of the therapeutic approaches for both non-neovascular and neovascular disease stages and provide a perspective of future directions including animal models and potential therapeutic approaches.

show abstract

Section: Treatmentmentioning

confidence: 99%

Macular telangiectasia type 2

Issa

Gillies

Chew

et al. 2013

Progress in Retinal and Eye Research

328

244

View full text Add to dashboard Cite

show abstract

“…Short-wavelength blue light threatens the RPE cells by increasing the risk of fundus diseases, comprising age-related macular degeneration (AMD) [ 1 , 2 ], diabetic retinopathy (DR) [ 3 , 4 ], idiopathic parafoveal telangiectasis (IPT) [ 5 , 6 ], retinal vein occlusion (RVO) [ 7 , 8 ], retinal artery occlusion (RAO) [ 9 , 10 ], central serous chorioretinopathy (CSC) [ 11 , 12 ], and polypoidal choroidal vasculopathy (PCV) [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

Fundus-Vascular Responses to Color Deviation Caused by Non-Oxidative Blue Filtering

Cai

Hao

Zeng

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Aims. Short-wavelength blue light damaged retina by the oxidative stress in the retinal pigment epithelial (RPE) cells. Filtering blue light from screen could reduce blue hazard, whereas it inevitably altered color-gamut coverage and color-deviation level. Although abnormal fundus-vascular density (FVD) sometimes indicated fundus disease, few researchers noticed its responses to the variation of color-gamut coverage and color-deviation level. Methods. In this study, we performed cellular experiments and analyzed the RPE cell viabilities (CVs) in spectrums with different blue (455-475 nm) ratios to describe the corresponding oxidative-stress levels. Further, we investigated the effects of color-gamut and deviation on FVD variations during the screen-watching task using human factor experiments with 30 participants (university students, including 17 males and 13 females, 21 to 30 years old). Results. RPE CVs were similar in different spectrums, implying that non-oxidative blue filtering hardly contributed to CV improvement. Color-deviation level seems to induce more significant effects on the visual function compared to color-gamut coverage, and MTF and FVD presents similar variation trends during the visual task. Conclusion. Oxidative-free blue filtering contributed little to decrease retinal oxidative stress yet caused color-deviation increase, which caused significant FVD reduction.

show abstract

“…A potential benefit of short-term intravitreal VEGF inhibition on foveal detachment in MacTel type 2 has been reported Windisch and Kozousek, 2008). The foveal anatomy regained its normal configuration with improved visual acuity in several retrospectively analyzed cases.…”

Section: Nonproliferative Stagementioning

confidence: 94%

Macular Telangiectasia Type 2

Heeren

Holz

Issa

2013

Microperimetry and Multimodal Retinal Imaging

View full text Add to dashboard Cite

Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules, retinal pigment plaques, foveal atrophy, and neovascular complexes. Fluorescein angiography shows telangiectatic capillaries predominantly temporal to the foveola in the early phase and a diffuse hyperfluorescence in the late phase. High-resolution optical coherence tomography (OCT) may reveal disruption of the photoreceptor inner segment-outer segment border, hyporeflective cavities at the level of the inner or outer retina, and atrophy of the retina in later stages. Macular telangiectasia type 2 shows a unique depletion of the macular pigment in the central retina and recent therapeutic trials showed that such depleted areas cannot re-accumulate lutein and zeaxanthin after oral supplementation. There have been various therapeutic approaches with limited or no efficacy. Recent clinical trials with compounds that block vascular endothelial growth factor (VEGF) have established the role of VEGF in the pathophysiology of the disease, but have not shown significant efficacy, at least for the nonneovascular disease stages. Recent progress in structure-function correlation may help to develop surrogate outcome measures for future clinical trials.In this review article, we summarize the current knowledge on macular telangiectasia type 2, including the epidemiology, the genetics, the clinical findings, the staging and the differential diagnosis of the disease. Findings using retinal imaging are discussed, including fluorescein angiography, OCT, adaptive optics imaging, confocal scanning laser ophthalmoscopy, and fundus autofluorescence, as are the findings using visual function testing including visual acuity and fundus-controlled microperimetry. We provide an overview of the therapeutic approaches for both non-neovascular and neovascular disease stages and provide a perspective of future directions including animal models and potential therapeutic approaches.

show abstract

Intravitreal bevacizumab compared with photodynamic therapy with verteporfin for group 2a parafoveal retinal telangiectasis

Cited by 6 publications

References 7 publications

Macular telangiectasia type 2

Macular telangiectasia type 2

Fundus-Vascular Responses to Color Deviation Caused by Non-Oxidative Blue Filtering

Macular Telangiectasia Type 2

Contact Info

Product

Resources

About